A phase-2 trial of low-dose pomalidomide in myelofibrosis.
about
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative NeoplasmsJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisCancer-treatment-induced neurotoxicity--focus on newer treatmentsAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsThe evolving treatment paradigm in myelofibrosisImmunomodulatory agents in myelofibrosis.Emerging drugs for myelofibrosis.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueAKT is a therapeutic target in myeloproliferative neoplasmsPhase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaProfile of pomalidomide and its potential in the treatment of myelofibrosis.How to manage the transplant question in myelofibrosis.One thousand patients with primary myelofibrosis: the mayo clinic experience.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Drug monographs: pomalidomide and ponatinib.A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceTherapeutic approaches in myelofibrosis.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsPomalidomide: first global approval.Treatment and management of myelofibrosis in the era of JAK inhibitorsClinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Pomalidomide for multiple myeloma.Emerging drugs for the treatment of myelofibrosis.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Immunotherapy based approaches in myelofibrosis.Pharmacologic management of myelofibrosis.Myelofibrosis: an update on drug therapy in 2016.
P2860
Q21285040-94FF1597-0156-47EF-887F-A55912220090Q24186554-7F6C8615-55BD-47F3-85A0-8A52F7B54731Q24201893-FE5F9B4C-89BB-4643-A811-123E9333F5F4Q26782604-3F6B0D53-D37E-4617-8083-D5FEBA8B2F8DQ26863610-3FB80169-490E-40D3-BACC-DC56B7BA4B34Q27021968-DFB304BF-3B0F-4D31-BED3-650E124BF0ACQ33401615-556F988E-5F70-4F92-B7D0-12DE75E1CFD7Q33404574-6C6467A2-7F1F-4568-9322-055E6BC97F1EQ33408049-A953E018-7CF8-4394-89E4-9BF132A6F024Q33430113-38897385-DB18-4706-988A-0848B1B629FEQ33436247-7F083203-692D-40D6-8118-D5F1D77C358CQ33459422-8E3640D1-8144-4D36-B680-D8F50D620770Q33623277-47CB0133-1CF4-4119-BAC7-4F18A0EF856EQ34146512-171074EC-0999-40E9-839D-F39FA5FAE0F2Q34253548-816D86E8-AB19-4449-9EC2-70D30FF5D92BQ34512203-2D713743-F2EB-4EF7-9901-786B7FFE4FA4Q35427915-ABF4956E-0931-4C58-B376-931C5785651DQ35865676-8D26E39A-0ED4-4FBA-9793-58EE9AB5FF27Q36512816-3E775ADF-4883-4E49-A672-891CB13F7C1CQ36612569-47F5D18E-6520-4D2E-ABB4-002E03493A8FQ36612613-BEC87E34-B22E-45DF-AE8B-640AEB096F0FQ36782943-8BFB74FF-7F64-45F6-94E4-9BDCC9235923Q37358344-F3F866D0-0D79-4A12-B782-722C26662647Q37619631-2F62A0A8-3C6D-430E-A00B-B9447D3B8213Q37740928-1D05949A-D86A-438F-9341-FABD55E20C52Q37860336-3311E6AD-A71F-4DA8-A35B-F7280AB2448CQ37877727-F420C28E-53AB-478B-9CE2-C8F79175DBE2Q37956603-2C005606-E799-410B-A547-21F1D3995019Q37978815-141827C6-0858-4F0E-8A59-919D6E03348EQ38014534-EB9029F3-FC46-4C4C-8F13-AD6A2542D1CEQ38031262-610ABC6C-00D8-457F-9F5A-82B0159EB49EQ38097747-0291A145-2B44-4CD9-9BDA-E7E2568A3D9CQ38132739-7E67F1E8-5236-4E33-AA05-83F2ACA6B144Q38242725-CF35A23A-D4C0-464F-8767-B0C844A28C12Q38255265-D576322B-C318-464D-B139-7C655960927AQ38543775-F6536466-56AA-4AD7-8636-D04AC9421560Q38613880-3B38C207-6541-4C27-86DB-5237CC2BFAD0Q38629189-8F2F7BAC-80F9-48C1-92E0-8B901B304590Q38965408-D3EFDC43-0C4A-4539-A8C1-3D73AEEF4E17Q38989215-B6520FFD-5907-46DA-B445-2A2833F4DBB4
P2860
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@ast
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@en
type
label
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@ast
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@en
prefLabel
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@ast
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@en
P2093
P2860
P356
P1433
P1476
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.254
P577
2010-11-05T00:00:00Z
P6179
1037260408